Practices

Mergers & Acquisitions

1,540+ M&A transactions for an aggregate value of $745+ billion since 2019

Why Cooley

180+ member team in 19 major business and technology centers in the US, Europe and Asia

Broad industry platform with clients across many industries and sophisticated capabilities in all practice areas

Excel in deals in the tech, life sciences, artificial intelligence, medical device and healthcare, consumer, education, defense and media industries

Given our market position in the medtech and life sciences sectors, we have handled a large number of life sciences M&A transactions, both public and private, and understand unique structuring issues for life sciences companies, including milestone structures, contingent value rights and option structures

Primary corporate counsel to 250+ public companies, giving us an unmatched perspective on market deal points and ability to facilitate introductions between buyers and sellers

Represent all categories of participants in transactions, including buyers, sellers, major stockholders, venture capitalists, lenders, financial advisors, management/founders, special board committees, individual investors, private equity funds, hedge funds and others 

Adept at handling all manner of transactions, including domestic and cross-border mergers and acquisitions, strategic deals including joint ventures, acquisitions of IP assets, patent cross-licenses, complex divestitures and spin-offs, takeover defense and shareholder activism counseling, and multibillion-dollar public company mergers

Robust SPAC experience and thought leaders in the area with a repository of market insight and guidance for businesses interested in the IPO alternative @ SPACtivity 

Market-leading IP, privacy, technology licensing, life sciences collaborations and licensing, regulatory, government contracts, credit finance, private equity, antitrust, employment, compensation and tax practices to support transactions

Read more

Recognition

  • Chambers: Ranked Band 1 for USA - Nationwide Corporate/M&A: Highly Regarded
  • Bloomberg: #2 for Global and US M&A by Deal Count (2023)
  • Bloomberg: #3 for UK M&A by Deal Count (2023)
  • Bloomberg: #1 for Global and US Mid-market M&A by Deal Count (2023)
  • Bloomberg: #2 for Global and US Mid-market M&A by Deal Value (2023)
  • Mergermarket: Top 5 for Global M&A by Deal Count (2023)
  • Mergermarket: Top 4 for US M&A by Deal Count (2023)
  • LSEG: Top 3 for Global Completed M&A by Deal Count (2023)
  • LSEG: Top 2 for US Completed M&A by Deal Count (2023)
  • LSEG: #2 for US Target Announced and Completed M&A by Deal Count (2023)
  • LMG Life Sciences: M&A Firm of the Year (2023)